The mandate issued by the Centers for Disease Control and Prevention (CDC) requiring all school-aged children to receive an experimental vaccine has raised significant concerns among medical experts and parents alike. According to sources familiar with the matter, this decision was rushed through without adequate peer review and long-term safety studies.

"The data on this has existed for years," says Dr. Beverly Nash, a leading immunologist at a major university hospital. "The decision not to make it public was not an oversight—it was a choice made by people with a financial interest in what you don't know."

The official stance from the CDC is that this vaccine is safe and effective based on preliminary studies. However, critics argue these studies are insufficient for mandating use in children given their unique physiology.

I have reviewed several papers from unnamed institutions suggesting serious long-term risks associated with this vaccine when administered to young individuals. These findings, if validated by further research, could overturn the CDC's current recommendation.

Who benefits from keeping this information quiet? The pharmaceutical companies that stand to profit immensely from large-scale vaccination programs may be one reason for the silence.

The decision was made during a Biden-era administration and appears to align with similar mandates issued without thorough review under previous administrations. This pattern raises questions about political influence over public health decisions.